Table I.
Association of Nek2 expression with clinicopathological characteristics of patients with HCC.
| Characteristics | Patients, no. | Nek2 positive, no. (%) | χ2 | P-value |
|---|---|---|---|---|
| Age, years | ||||
| <60 | 17 | 11 (64.7) | 0.632 | 0.426 |
| ≥60 | 35 | 19 (54.3) | ||
| Tumor size, cm | ||||
| <5 | 28 | 17 (60.9) | 1.213 | 0.271 |
| ≥5 | 24 | 13 (54.2) | ||
| Hepatic function | ||||
| Child A | 15 | 9 (60) | 0.001 | 0.971 |
| Child B | 37 | 21 (56.7) | ||
| Edmondson stage | ||||
| Stage I and II | 42 | 22 (52.4) | 4.434 | 0.037a |
| Stage III and IV | 10 | 8 (80) | ||
| Portal vein tumor thrombus | ||||
| Positive | 10 | 9 (90) | 5.295 | 0.032a |
| Negative | 42 | 21 (50) | ||
| AFP | ||||
| Positive | 44 | 24 (54.5) | 1.160 | 0.281 |
| Negative | 8 | 6 (75.0) |
a
P<0.05. HCC, hepatocellular carcinoma; AFP, α-fetoprotein.